Home » Topics » BioWorld Science

BioWorld Science
RSS

First patient dosed in phase I study of RBN-2397

Sep. 5, 2019

Tiziana Life Sciences reports positive phase IIa data for milciclib in HCC

Sep. 5, 2019

CC-90011 demonstrates promising activity in models of SCLC

Sep. 5, 2019

Preclinical and phase I data presented for SAR-439859

Sep. 5, 2019

Discovery of novel R-PTP-sigma inhibitors to promote hematopoietic stem cell regeneration

Sep. 5, 2019

Soluble RANKL inhibition may prevent tumor metastasis to bone

Sep. 5, 2019

Antimalarial kinase inhibitor identified at the University of Glasgow

Sep. 5, 2019

CRISPR targets fat cells, improves metabolism

Sep. 5, 2019

Evaluation of the effects of atractylenolide I in a new mouse model of cancer cachexia

Sep. 5, 2019

JMJD6 predicts poor prognosis in ovarian cancer and can be a new therapeutic target

Sep. 5, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...